Table 1. Regimens for adult Burkitt-type leukemia/lymphoma.
| Study | Therapy | No. | Age (yrs) | %CR | % Continuous CR (X yrs) | % OS (X yrs) | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Median | % ≥ 60 [% ≥ 55] | ||||||
| No rituximab | |||||||
|
| |||||||
| Hoelzer [89] | B-NHL83 | 24 | 33 | 0 | 63 | 50 (8) | 49 (8) |
| B-NHL86 | 35 | 36 | 10 | 74 | 71 (4) | 51 (4) | |
| Hoelzer [40] | B-NHL 90 | 45 | — | [100] | 71 | — | 39 (6) |
| Magrath [90] | 89-C-41 (CODOX-M/IVAC) | 20 | 25 | 0 | 89 | 89 (2) | 74 (4) |
| Hyper-CVAD | 26 | 58 | 46 | 81 | 61 (3) | 49 (3) | |
| Thomas [32] | Age < 60 yrs | 14 | 38 | — | 93 | 83 (3) | 77 (3) |
| Age ≥ 60 yrs | 12 | — | — | — | — | 17 (3) | |
| CALGB 9521 | |||||||
| Rizzieri [91] | Cohort 1 | 52 | 44 | 19 | 79 | 66 (3) | 54 (3) |
| Cohort 2 | 40 | 50 | 23 | 68 | 67 (3) | 50 (3) | |
| Di Nicola [92] | CMVVP-16/Ara-C/CDDP | 22 | 36 | — | 77 | 68 (2) | 77 (2) |
| Lacasce [93] | Modified CODOX-M/IVAC | 14 | 47 | — | 86 | 64 (2) | 71 (2) |
| Divine [94] | LMB95 | 72 | 33 | — | 72 | — | 70 (2) |
| Hyper-CVAD | 48 | 48 | 33 | 85 | 60 (3) | 53 (3) | |
| Thomas [38] | Age < 60 yrs | 25 | — | — | — | 73 (3) | 70 (3) |
| Age ≥ 60 yrs | 23 | — | — | — | 44 (3) | 19 (3) | |
| Mead [95] | Modified CODOX-M/IVAC | 53 | 37 | 9 | — | — | 67 (2) |
|
| |||||||
| With rituximab | |||||||
|
| |||||||
| Hyper-CVAD + rituximab | 31 | 46 | 29 | 86 | 88 (3) | 89 (3) | |
| Thomas [38] | Age < 60 yrs | 22 | — | — | — | 88 (3) | 90 (3) |
| Age ≥ 60 yrs | 9 | — | — | — | 100 (3) | 89 (3) | |
| Oriol [46] | PETHEMA* | 17 | 36 | 0 | 88 | 93 (2) | 82 (2) |
| GMALL B-ALL/NHL 2002 | |||||||
| BL | |||||||
| Hoelzer [42] | Age < 55 yrs | 146 | 36 | [18] | 90 | — | 91 (3) |
| Age ≥ 55 yrs | — | 84 (3) | |||||
| B-ALL | |||||||
| Age < 55 yrs | 84 | 46 | [41] | 83 | — | 79 (3) | |
| Age ≥ 55 yrs | — | 39 (3) | |||||
— Not available or not reported;
Adopted from GMALL B-ALL/NHL 2002
CR, complete remission; OS, overall survival; NHL, non-Hodgkin lymphoma; CODOX-M/IVAC, cyclophosphamide, vincristine, doxorubicin, high dose methotrexate alternating with ifosfamide, etoposide, high dose cytarabine; hyper-CVAD, fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high dose methotrexate and cytarabine; CALGB, Cancer and Leukemia Group B; CMVVP-16/Ara-C/CDDP, cyclophosphamide, doxorubicin, high dose methotrexate, vincristine, etoposide, cytarabine, cisplatin; LMB, Lymphoma Malignancy B; PETHEMA, Programa para el Estudio de la Terapéutica en Hemopatías Malignas; GMALL, German Multicenter Study Group for Adult ALL; BL, Burkitt lymphoma; B-ALL, mature B-cell ALL